Advertising Disclaimer
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View eLetters
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Angus, D. C.
Right arrow Articles by Roberts, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Angus, D. C.
Right arrow Articles by Roberts, M. S.
Related Collections
Right arrow Office Practice
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
PEDIATRICS Vol. 112 No. 6 December 2003, pp. 1351-1360

Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the United States

Derek C. Angus, MB, ChB, MPH*, Gilles Clermont, MD*, R. Scott Watson, MD, MPH*, Walter T. Linde-Zwirble{ddagger}, Reese H. Clark, MD§, Mark S. Roberts, MD, MPP||

* Clinical Research, Investigation, and Systems Modeling of Acute Illness (CRISMA) Laboratory, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
{ddagger} Health Process Management, LLC, Doylestown, Pennsylvania
§ Pediatrix Medical Group, Inc, Sunrise, Florida
|| Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania

Objective. Two recent randomized controlled trials (RCTs) reported that inhaled nitric oxide (iNO) decreased the incidence of extracorporeal membrane oxygenation (ECMO) or death in term and near-term newborns with hypoxic respiratory failure. Our objective was to estimate the cost-effectiveness ratio of iNO in this population.

Methods. We studied 1000 simulation cohorts (n = 483 for each cohort) of term/near-term newborns with hypoxemic respiratory failure. We conducted our study following US Public Health Service Panel on Cost-Effectiveness in Health and Medicine guidelines, adopting the US societal perspective. We constructed a decision tree reflecting iNO use, subsequent ECMO use, death, and long-term neurologic and respiratory morbidity in survivors, as determined from the combined outcomes of the 2 RCTs (n = 483). We estimated costs on the basis of length-of-stay data for the initial episode of care from 1 of the RCTs, unit costs from administrative data sets, and current pricing for iNO. We ran a Monte Carlo simulation to generate estimates of differences in costs and effects at 1 year, along with the stochastic uncertainty around these estimates. We expressed effects as quality-adjusted survival, assuming quality of life = 1 with no comorbidity, 0.7 with 1 comorbidity, and 0.49 (0.7 x 0.7) with 2 comorbidities. We constructed a base case, in which iNO was initiated at tertiary care ECMO centers (mimicking the RCTs) and a Public Health Service Panel on Cost-effectiveness in Health and Medicine reference case, in which iNO was initiated at the local hospital before transfer (mimicking real-world practice). We exposed our assumptions to a sensitivity analysis.

Results. Direct application of the trial results (base case) suggested that iNO was both more effective and cheaper (cost savings of $1880 per case despite acquisition costs of $5150, predominantly as a result of decreased need for ECMO), with 84.6% probability that the cost-effectiveness ratio was better than $100 000 per quality-adjusted life-year. Under the reference case, iNO was also more effective (though slightly less so) and was even cheaper (cost savings of $4400 per case), with 71.6% probability that iNO was cheaper and more effective and 91.6% probability that the cost effectiveness ratio was better than $100 000 per quality-adjusted life-year. Sensitivity analyses showed these estimates to be sensitive to patient selection and the price of iNO but insensitive to assumptions regarding quality of life.

Conclusions. From a US societal perspective, iNO has a favorable cost-effectiveness profile when initiated either at ECMO centers or at local hospitals in term/near-term neonates with hypoxemic respiratory failure.

Key Words: newborn • nitric oxide • respiratory failure • cost-effectiveness • ECMO

Abbreviations: ECMO, extracorporeal membrane oxygenation • iNO, inhaled nitric oxide • RCT, randomized controlled trial • NINOS, Neonatal Inhaled Nitric Oxide Study • CINRGI, Clinical Inhaled Nitric Oxide Research Group Initiative • PCEHM, Panel on Cost-effectiveness in Health and Medicine • ICU, intensive care unit; CI, confidence interval • QALY, quality-adjusted life-year

Received for publication Apr 1, 2002; Accepted Mar 28, 2003.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
J. A. F. Zupancic, A. M. Hibbs, L. Palermo, W. E. Truog, A. Cnaan, D. M. Black, P. L. Ballard, S. R. Wadlinger, R. A. Ballard, and and the NO CLD Trial Group
Economic Evaluation of Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation
Pediatrics, November 1, 2009; 124(5): 1325 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
R. S. Watson, G. Clermont, J. P. Kinsella, L. Kong, R. E. Arendt, G. Cutter, W. T. Linde-Zwirble, S. H. Abman, D. C. Angus, and on behalf of the Prolonged Outcomes After Nitric O
Clinical and Economic Effects of iNO in Premature Newborns With Respiratory Failure at 1 Year
Pediatrics, November 1, 2009; 124(5): 1333 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
C. S. Beardsmore, J. Westaway, H. Killer, R. K. Firmin, and H. Pandya
How Does the Changing Profile of Infants Who Are Referred for Extracorporeal Membrane Oxygenation Affect Their Overall Respiratory Outcome?
Pediatrics, October 1, 2007; 120(4): e762 - e768.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
I. Griebsch, J. Coast, and J. Brown
Quality-Adjusted Life-Years Lack Quality in Pediatric Care: A Critical Review of Published Cost-Utility Studies in Child Health
Pediatrics, May 1, 2005; 115(5): e600 - e614.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Nurs.Home page
Other articles noted: 06 Feb 2004 to 16 Apr 2004
Evid. Based Nurs., July 1, 2004; 7(3): e3 - e3.
[Full Text] [PDF]

Home page
 CirculationHome page
F. Ichinose, J. D. Roberts Jr, and W. M. Zapol
Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential
Circulation, June 29, 2004; 109(25): 3106 - 3111.
[Full Text] [PDF]

Home page
 PediatricsHome page
T. W. R. Hansen, D. Field, C. Normand, D. Elbourne, D. C. Angus, G. Clermont, R. S. Watson, and W. T. Linde-Zwirble
Inhaled Nitric Oxide and the Societal Perspective
Pediatrics, June 1, 2004; 113(6): 1849 - 1851.
[Full Text]

Home page
 PediatricsHome page
D. Field, C. Normand, and D. Elbourne
Cost-Effectiveness of Inhaled Nitric Oxide in the Treatment of Neonatal Respiratory Failure in the US
Pediatrics, December 1, 2003; 112(6): 1422 - 1423.
[Full Text] [PDF]

eLetters:

Read all eLetters

Cost-effectiveness of inhaled nitric oxide
Ronald W. Day
Pediatrics Online, 13 Jan 2004 [Full text]
In Response to Dr. Day
Derek C Angus, et al.
Pediatrics Online, 15 Mar 2004 [Full text]